AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02322099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate and colecalciferol
Description: Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
Study NCT02322099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
Study NCT02322099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
Study NCT03249948 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vector change defibrillation
Description: Defibrillation using pad placement in anterior-posterior position.
Study NCT03249948 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Double-sequential defibrillation
Description: Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
Study NCT00002941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00002941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study NCT00002941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00621088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intertan
Description: Operations performed either with a Sliding Hip Screw or a nail (Intertan)
Study NCT02867163 — intervention group
Intervention type: DRUG
Intervention: Tranexamic Acid
Description: Intravenous or local administration of TXA, in any dosage
Study NCT01250652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: 20 mg levocetirizine for 5 days
Study NCT01250652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine plus Hydroxyzine
Description: 24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
Study NCT02251158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir oral solution
Study NCT02251158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tipranavir capsules
Study NCT02251158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir oral solution
Study NCT02251158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir soft gel capsules
Study NCT02251158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat breakfast
Study NCT01316029 — intervention group
Intervention type: PROCEDURE
Intervention: Okada Purifying Therapy
Description: Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
Study NCT01661946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
Study NCT01661946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
Study NCT00987090 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic and neuropsychologic evaluation
Description: evaluation at the inclusion and 18 months after
Study NCT00987090 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinic and neuropsychologic evaluation
Description: evaluation at the inclusion and 18 months after
Study NCT00987090 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: intervention at the inclusion and 18 months after
Study NCT00690794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
Study NCT00690794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
Study NCT01187654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AC133
Description: intra coronary injection of bone marrow derived AC133+ cells
Study NCT00987090 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: intervention at the inclusion and 18 months after
Study NCT00987090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET
Description: 18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
Study NCT00987090 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PET
Description: 18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
Study NCT00987090 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Apolipoprotein E genotyping
Description: genotyping at the inclusion
Study NCT00987090 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Apolipoprotein E genotyping
Description: genotyping at the inclusion
Study NCT00987090 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Study of cerebrospinal fluid
Description: intervention at the inclusion
Study NCT01886885 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mindfulness Based Chronic Pain Management Intervention
Description: Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
Study NCT04322162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASAP Intervention Quality Improvement Protocol
Description: The intervention program includes: (1) a systems redesign Virtual Collaborative, and; (2) data monitoring and is designed to aid each of the 6 participating VAMCs in developing, implementing, and evaluating the implementation of an acute OSA testing and treatment protocol for ischemic stroke/TIA patients. The sites will choose a diagnostic strategy (i.e., unattended polysomnography \[PSG\]/home sleep test \[HST\], in-laboratory PSG, direct to auto-titrating \[auto\]-PAP) and a therapeutic strategy (i.e., in-laboratory PAP titration, auto-PAP). The intervention will employ 3 implementation strategies: (1) local adaptation; (2) external facilitation, and; (3) audit and feedback.
Study NCT04147507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Music Therapy
Description: Music group (N=15) will receive listen to music therapy passively for 20 minutes/day, 5 days/week for 4 weeks, along with lifestyle modifications. Music therapy will be provided via headphones in an isolated quiet non-disrupted room, with room temperature maintained between 20-22 degree Celsius and having medium light intensity. Participants would be instructed to listen to music with eyes closed in sitting position, back supported in comfortable position on a chair. The participants will be given 5 minutes' rest in sitting position before and after each music therapy session.
Study NCT04147507 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Control group (N=15) would receive only lifestyle modification. Handout of lifestyle modification according to the Seventh Joint National Committee (JNC VII) report guidelines will be given to all participants. Participants would be instructed to not participate in any form of physical activity and to focus only on two components from the guideline which includes practice the DASH eating plan (diet rich in fruits and vegetables, low fat dairy or unsaturated fat) and limit the daily sodium intake (less than 100 mmol per day).
Study NCT01191632 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: one time radiation
Description: Radiation: one time Radiation with an intensity of~0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery
Study NCT01191632 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No Radiation
Description: Control group with 0Gy
Study NCT03846973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: intravenous infusion of 1 g infusion to be given and completed over 8 h in the hospital
Study NCT03846973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (normal saline) infusion to be given and completed over 8 h in the hospital
Study NCT02119468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixazomib citrate
Description: Given orally
Study NCT02119468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT02119468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Given orally
Study NCT00496613 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mini-Mental State Exam and Blood draw
Description: The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
Study NCT00496613 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mini-Mental State Exam and Blood Draw
Description: The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
Study NCT03802656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Vertebral Body Tethering
Description: Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
Study NCT05656391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Treatment vs control bread
Description: Consumption of 200 grams per day of either treatment or control bread for eight weeks
Study NCT05656391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment vs control bread
Description: Consumption of 200 grams per day of either treatment or control bread for eight weeks
Study NCT02590419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrightMatter™ products
Description: BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively.
Study NCT00259038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carperitide
Study NCT00259038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03094611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study NCT01451151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured dermal and epidermal cells
Description: A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
Study NCT03082417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation
Description: The PAINFREE Initiative is a Multifaceted intervention:~1. Educating and providing point-of-care tools to nurses working at Emergency Department to improve pain management in older adults with fractures~2. Educating and providing point of care tools to Emergency Departments physicians working at Emergency Department to improve pain management in older adults with fractures~3. Inform the patients and their family about how to better manage the pain after a fracture
Study NCT02954302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PrPD with proximal Roux-en-y gastrojejunal anastomosis
Description: the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach. The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction. After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion. The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
Study NCT02954302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional PrPD
Description: After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
Study NCT00518843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT-BN
Description: Mobilizing parents to curtail binge eating and purging
Study NCT00518843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPT
Description: Supportive the individual patient to explore factors that might underlie the eating disorder
Study NCT04089436 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CSF sampling
Description: CSF sampling by lumbar puncture
Study NCT04089436 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling by blood test
Study NCT04089436 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal and rectal sampling
Description: Nasopharyngeal and rectal sample by swabbing
Study NCT02562989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-6240, ~185 MBq
Description: IV dose of \~185 MBq \[18F\]MK-6240
Study NCT02562989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-6240, ~160 MBq
Description: IV dose of \~160 MBq \[18F\]MK-6240
Study NCT04606641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional tasks with mirror therapy
Description: In this group a mirror will be placed in the sagittal plane of patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror. Then the patient will be asked to perform functional tasks
Study NCT04606641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional tasks without mirror therapy
Description: The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks
Study NCT02681718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community health worker education
Description: Diabetes self-management education by community health workers
Study NCT02681718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cell phone text messaging
Description: Diabetes self-management education through cell phone text messaging
Study NCT04714723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Programmed smartphone intervention
Description: Interactive programmed lifestyle education based on smartphone for six month
Study NCT04714723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Programmed smartphone plus dietitian intervention
Description: Interactive programmed lifestyle education based on smartphone plus dietitians support for six month
Study NCT01187654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC
Description: intra coronary injection of bone marrow derived MNC
Study NCT01187654 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: autologous serum injection
Study NCT01692288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First Born® Program home visiting services
Description: Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
Study NCT03248388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argus II Eyeglasses
Description: The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
Study NCT03655509 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dynamic test ACTH stimulation
Study NCT03442504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FES PET/CT
Description: There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~* The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~* The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service.
Study NCT03239639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning education session
Description: Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
Study NCT03239639 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Wait list control
Description: No intervention
Study NCT03355404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standing patient
Description: patient goes standing to the surgery room
Study NCT03292341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviews
Description: Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs
Study NCT03292341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatmentchoice Decisional Tool
Description: Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
Study NCT03292341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients and physicians fill out questionnaires on the usual care, Delphi study
Study NCT03248388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORCAM
Description: ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
Study NCT03292341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviews with stakeholders
Description: Interviews with stakeholders Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.